2003 OPEN FORUM Abstracts
FACEMASK DESIGN AND Nebulizer flow GOVERN FACIAL DEPOSITION OF AEROSOLS
GC Smaldone MD, PhD1,S Sangwan MD2, A Shah MD1 and
Institutions: 1SUNY at Stony Brook, NY-11794,2Mercy Catholic Medical Center, Darby, PA
Rationale: Pediatric aerosol therapy using nebulizers and facemasks can result in deposition on the face and eyes1. Facemask design and nebulizer flow may be important determinants of this deposition.
Methods: Facemask leak, drug substance delivery (Inhaled Mass) and facial deposition of radio-labeled test aerosols were studied in vitro with a gamma camera and a face facsimile1. Facial and eye deposition were measured for a commercially available, tight fitting and non-vented facemask. Mechanistic design modifications (creating different vents) were made and deposition patterns compared at two nebulizer flow rates.
RESULTS: Deposition and Inhaled Mass as percent nebulizer charge
|Facial Deposition||Eye Deposition||Inhaled Mass|
|@ 4 Lpm||@ 8 Lpm||@ 4 Lpm||@ 8 Lpm||@ 4 Lpm||@ 8 Lpm|
Conclusions: For non-vented masks, deposition on the face and eyes was similar to delivery to the lungs and increased with nebulizer flow. Modifications to the mask designed to reduce the ballistic component of the particles decreased facial and eye deposition while increasing delivery to the lungs.
1AJRCCM. 165:8; A744. 2002.
Source of funding: AstraZeneca